Found: 57
Select item for more details and to access through your institution.
Cancer, more than a "COVID-19 co-morbidity".
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1107384
- By:
- Publication type:
- Article
Planning for post‐pandemic cancer care delivery: Recovery or opportunity for redesign?
- Published in:
- CA: A Cancer Journal for Clinicians, 2021, v. 71, n. 1, p. 34, doi. 10.3322/caac.21644
- By:
- Publication type:
- Article
Characterization of FOLH1 Expression in Renal Cell Carcinoma.
- Published in:
- Cancers, 2024, v. 16, n. 10, p. 1855, doi. 10.3390/cancers16101855
- By:
- Publication type:
- Article
The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression.
- Published in:
- Cancers, 2023, v. 15, n. 24, p. 5721, doi. 10.3390/cancers15245721
- By:
- Publication type:
- Article
The Current and Future Promises of Combination Radiation and Immunotherapy for Genitourinary Cancers.
- Published in:
- Cancers, 2023, v. 15, n. 1, p. 127, doi. 10.3390/cancers15010127
- By:
- Publication type:
- Article
Assessing Unique Risk Factors for COVID-19 Complications Among Cancer Patients: A Multi-ethnic Cohort Study.
- Published in:
- Journal of Immigrant & Minority Health, 2023, v. 25, n. 3, p. 624, doi. 10.1007/s10903-022-01413-w
- By:
- Publication type:
- Article
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 316
- By:
- Publication type:
- Article
Rede? ning the Clinical States of Prostate Cancer in the Modern Era.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 4, p. 169
- By:
- Publication type:
- Article
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
- Published in:
- Oncologist, 2024, v. 29, n. 4, p. 324, doi. 10.1093/oncolo/oyad298
- By:
- Publication type:
- Article
Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 7, p. 596, doi. 10.1093/oncolo/oyad102
- By:
- Publication type:
- Article
COVID-19 Outcomes Among Patients With Cancer: Observations From the University of California Cancer Consortium COVID-19 Project Outcomes Registry.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 398, doi. 10.1093/oncolo/oyac038
- By:
- Publication type:
- Article
Temporal Trends and Predictors in the Use of Stereotactic Body Radiotherapy for Treatment of Metastatic Renal Cell Carcinoma in the U.S.
- Published in:
- Oncologist, 2021, v. 26, n. 5, p. e905, doi. 10.1002/onco.13736
- By:
- Publication type:
- Article
Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy.
- Published in:
- PLoS ONE, 2022, v. 17, n. 11, p. 1, doi. 10.1371/journal.pone.0272022
- By:
- Publication type:
- Article
Treatment Landscape of Renal Cell Carcinoma.
- Published in:
- Current Treatment Options in Oncology, 2023, v. 24, n. 12, p. 1889, doi. 10.1007/s11864-023-01161-5
- By:
- Publication type:
- Article
A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 2, p. 311, doi. 10.1002/cncr.28972
- By:
- Publication type:
- Article
Impact of age on treatment response in men with prostate cancer treated with radiotherapy.
- Published in:
- BJUI Compass, 2022, v. 3, n. 3, p. 243, doi. 10.1002/bco2.132
- By:
- Publication type:
- Article
Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes.
- Published in:
- JAMA Network Open, 2024, v. 7, n. 3, p. e242976, doi. 10.1001/jamanetworkopen.2024.2976
- By:
- Publication type:
- Article
Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
- Published in:
- AUANews, 2022, v. 27, p. 16
- By:
- Publication type:
- Article
Neoadjuvant Intense ADT prior to Radical Prostatectomy: Steps toward a Shift in Paradigm.
- Published in:
- AUANews, 2021, v. 26, n. 8, p. 22
- By:
- Publication type:
- Article
BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
- Published in:
- Medicina (1010660X), 2022, v. 58, n. 12, p. 1818, doi. 10.3390/medicina58121818
- By:
- Publication type:
- Article
Prostate Cancer 2012: Where Do We Stand and Where Are We Heading?
- Published in:
- Oncology (08909091), 2012, v. 26, n. 12, p. 1222
- By:
- Publication type:
- Article
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer.
- Published in:
- Prostate, 2021, v. 81, n. 7, p. 433, doi. 10.1002/pros.24123
- By:
- Publication type:
- Article
Tumor cell heterogeneity and resistance; report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting.
- Published in:
- Prostate, 2019, v. 79, n. 3, p. 244, doi. 10.1002/pros.23729
- By:
- Publication type:
- Article
Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
- Published in:
- 2022
- By:
- Publication type:
- journal article
A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer.
- Published in:
- Advances in Therapy, 2020, v. 37, n. 12, p. 4910, doi. 10.1007/s12325-020-01509-5
- By:
- Publication type:
- Article
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
- Published in:
- Prostate, 2024, v. 84, n. 3, p. 292, doi. 10.1002/pros.24650
- By:
- Publication type:
- Article
Adjuvant Therapy in Renal Cell Carcinoma: Are we ready for prime time?
- Published in:
- Kidney Cancer (2468-4562), 2023, v. 7, n. 1, p. 1, doi. 10.3233/KCA-220014
- By:
- Publication type:
- Article
Trends of kidney cancer burden from 1990 to 2019 in European Union 15 + countries and World Health Organization regions.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-25485-8
- By:
- Publication type:
- Article
New Drug Approvals in Prostate Cancer and Their Effect on the Treatment Landscape.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 6, p. 321
- By:
- Publication type:
- Article
The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 12, p. 2191, doi. 10.1002/cncr.35247
- By:
- Publication type:
- Article
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate‐risk or high‐risk prostate cancer: Results of part 2 of a randomized phase 2 trial
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 9, p. 1629, doi. 10.1002/cncr.35170
- By:
- Publication type:
- Article
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune‐checkpoint inhibitor‐related biomarkers.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 24, p. 3884, doi. 10.1002/cncr.34982
- By:
- Publication type:
- Article
Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 4, p. 770, doi. 10.1002/cncr.33991
- By:
- Publication type:
- Article
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 6, p. 840, doi. 10.1002/cncr.33328
- By:
- Publication type:
- Article
Outcomes of Black men with prostate cancer treated with radiation therapy in the Veterans Health Administration.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Low-Value Prostate-Specific Antigen Screening in Older Males.
- Published in:
- JAMA Network Open, 2023, v. 6, n. 4, p. e237504, doi. 10.1001/jamanetworkopen.2023.7504
- By:
- Publication type:
- Article
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 6, p. e2216379, doi. 10.1001/jamanetworkopen.2022.16379
- By:
- Publication type:
- Article
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US.
- Published in:
- Quality of Life Research, 2023, v. 32, n. 11, p. 3209, doi. 10.1007/s11136-023-03468-0
- By:
- Publication type:
- Article
SMART COVID Navigator, a Clinical Decision Support Tool for COVID-19 Treatment: Design and Development Study.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
- Published in:
- Genome Medicine, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13073-021-00969-w
- By:
- Publication type:
- Article
Association of Health-Care System and Survival in African American and Non-Hispanic White Patients With Bladder Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2022, v. 114, n. 4, p. 600, doi. 10.1093/jnci/djab219
- By:
- Publication type:
- Article
Characterization and impact of non‐canonical WNT signaling on outcomes of urothelial carcinoma.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 7, p. 1, doi. 10.1002/cam4.7148
- By:
- Publication type:
- Article
Analysis of CDK12 alterations in a pan‐cancer database.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 3, p. 753, doi. 10.1002/cam4.4483
- By:
- Publication type:
- Article